NeuroSense Therapeutics (NeuroSense Therapeutics) Pre-Tax Income : $-11.28 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is NeuroSense Therapeutics Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. NeuroSense Therapeutics's pretax income for the three months ended in Dec. 2023 was $-2.95 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was $-11.28 Mil. NeuroSense Therapeutics's pretax margin was %.

NeuroSense Therapeutics Pre-Tax Income Historical Data

The historical data trend for NeuroSense Therapeutics's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuroSense Therapeutics Pre-Tax Income Chart

NeuroSense Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Pre-Tax Income

-1.22

-2.83

-4.04

-12.34

-11.28

NeuroSense Therapeutics Quarterly Data
	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Pre-Tax Income	Get a 7-Day Free Trial										-3.15	-3.89	-5.23	0.78	-2.95

Competitive Comparison of NeuroSense Therapeutics's Pre-Tax Income

For the Biotechnology subindustry, NeuroSense Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NeuroSense Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NeuroSense Therapeutics's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where NeuroSense Therapeutics's Pre-Tax Income falls into.

NeuroSense Therapeutics Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

NeuroSense Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-13.302	+	2.394	+	-0.011	+	0.178	+	-0.539
	=	-11.28

NeuroSense Therapeutics's Pretax Income for the quarter that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-3.287	+	0	+	2.197	+	-3.715	+	1.855
	=	-2.95

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.28 Mil.

NeuroSense Therapeutics (NAS:NRSN) Pre-Tax Income Explanation

NeuroSense Therapeutics's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-2.95	/	0
	=	%

NeuroSense Therapeutics Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of NeuroSense Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

NeuroSense Therapeutics (NeuroSense Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuroSense Therapeutics Ltd (NAS:NRSN) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

11 HaMenofim Street, Building B, Herzliya, ISR, 4676670

Website

https://www.neurosense-tx.com

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.